SCHEMBL6786590

SCHEMBL6786590

CCOC(=O)c1cc(NC(=O)Nc2ccc(Oc3ccccc3)cc2)ccc1NC(=O)/C=C(/C)c1ccc2ccccc2c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TERT O14746 5/20 0.55
LMNA P02545 2/20 0.46
MAPT P10636 4/20 0.45
ALDH1A1 P00352 2/20 0.45
THRB P10828 1/20 0.45
NPC1 O15118 3/20 0.44
RAB9A P51151 3/20 0.44
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
CA12 O43570 2/20 0.44
CA1 P00915 2/20 0.44
CA2 P00918 2/20 0.44
CA9 Q16790 2/20 0.44
HPGD P15428 1/20 0.44
CRHBP P24387 1/20 0.44
CRHR2 Q13324 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.43
TRPV1 Q8NER1 2/20 0.42
NR1H4 Q96RI1 1/20 0.42
MCHR1 Q99705 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6783765 0.95 TERT (0.59) TERTLMNAMAPTALDH1A1NPC1
SCHEMBL6790433 0.90 TERT (0.66) TERTMAPTNPC1RAB9AMEN1
SCHEMBL6791830 0.89 TERT (0.56) TERTLMNAMAPTALDH1A1NPC1
SCHEMBL6791907 0.85 TERT (0.50) TERTLMNAMAPTALDH1A1NPC1
SCHEMBL6784598 0.84 TERT (0.53) TERTLMNAALDH1A1NPC1RAB9A
SCHEMBL6788362 0.83 TERT (0.53) TERTLMNAALDH1A1RAB9AKMT2A
SCHEMBL6786594 0.83 TERT (0.72) TERTMAPTNPC1RAB9AMEN1
SCHEMBL6788177 0.83 TERT (0.55) TERTLMNAALDH1A1CA12CA1
SCHEMBL6784867 0.82 TERT (0.55) TERTLMNAMAPTALDH1A1MEN1
SCHEMBL6784482 0.81 TERT (0.53) TERTLMNAMAPTALDH1A1CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6727250-B2 ADMINISTERING COMPOUNDS SUCH AS TRANS-3-(NAPHTH-2-YL)-BUT-2-ENOIC ACID-N-(2-CARBOXY-PHENYL)-AMIDE OR LIKE FOR THERAPY OF CONDITIONS ASSOCIATED WITH INCREASED TELOMERASE ACTIVITY, E.G. TUMOUR DISEASES BOEHRINGER INGELHEIM PHARMA KG (DE) 2004-04-27 US disclosed
US-20020099089-A1 Carboxylic acid amides, pharmaceutical compositions containing these compounds, their use and preparation BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2002-07-25 US disclosed
US-6362210-B1 ANTITUMOR, ANTICANCER AGENT BOEHRINGER INGELHEIM PHARMA KG (DE) 2002-03-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020099089-A1 Carboxylic acid amides, pharmaceutical compositions containing these compounds, their use and preparation TERT, NAT1, POT1 TERT 1/4885LMNA 169/4885MAPT 1221/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.